IFNG and ovarian carcinoma: Similar enhancement of activation and IFNγ production with mbIL12 was shown against human patient-derived TAG72+ gastric and ovarian cancer ascites cells, with little to no impact on the targeting of normal primary human cells (Fig. S14).